Aalborg University Hospital
- Address
- lock Available on a paid plan
Female Urogenital Health and Pregnancy Complications
At Aalborg University Hospital, clinical research in this area focuses on pregnancy complications linked to antiphospholipid antibodies. The studies are aimed at understanding how to improve pregnancy outcomes for women affected by these immune-related conditions.
- Research on pregnancy outcome in women with antiphospholipid antibodies
- Evaluation of new approaches to support safer pregnancies
- Clinical interest in reducing complications connected to APS
This work reflects a patient-centered effort to improve maternal health and guide better care for women facing high-risk pregnancies.
Immune System Diseases
The Department of Rheumatology is also involved in trials related to immune system diseases, with a particular focus on APS and antiphospholipid antibodies. These studies explore whether targeted treatment can improve clinical outcomes in affected patients.
- Studies centered on APS
- Research into antiphospholipid antibodies and their clinical impact
- Testing treatment strategies to improve disease-related outcomes
The research supports a better understanding of immune-driven disease mechanisms and how they may be managed more effectively in everyday care.
Pathological Conditions, Signs and Symptoms
Another key area at this site includes broader investigation of pathological conditions and related symptoms associated with autoimmune complications. The trials aim to clarify how specific therapies may influence disease expression and overall patient wellbeing.
- Clinical investigation of symptoms and complications linked to APS
- Assessment of treatment effectiveness in immune-related conditions
- Efforts to improve diagnosis and management of complex clinical presentations
With a strong investigator base, Aalborg University Hospital contributes to practical research that may help refine care for patients with challenging immune and pregnancy-related disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 29 therapeutic areas and 15 of 542 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 507 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 72 by active trials.
- 1Region Hovedstaden21active
lock +71 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB34trials
lock +44 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 111 other sites in Denmark
Therapeutic Area Benchmark — Denmark
Select a therapeutic area to compare against other sites in Denmark.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Denmark
Market Share
Country: Denmark
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Aalborg University Hospital
lock Showing 1 of 335 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 542 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 24 | Unknown | 2018-12-05 | 2026-07-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.